Prevalence of Migraine in General Spanish Population; Factors Related and Use of Health Resources.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
23 10 2021
Historique:
received: 22 09 2021
revised: 20 10 2021
accepted: 21 10 2021
entrez: 13 11 2021
pubmed: 14 11 2021
medline: 23 11 2021
Statut: epublish

Résumé

Migraine is a common neurological disorder considered the second most disabling condition worldwide. Its prevalence ranges from 2.6% to 21.7% in population studies. This study aimed to know the prevalence of diagnosed and undiagnosed migraine in the general Spanish adult population, their health care use, and factors related. A descriptive cross-sectional study was undertaken with 23,089 individuals >15 years from the 2017 Spanish National Health Survey. Three groups were defined: people diagnosed with migraine (DM), people reporting undiagnosed migraine (UM) and people without migraine. Sociodemographic, clinical and use of health resources data were collected. The scales Duke Social Support Index (DSSI) and General Health Questionnaire (GHQ-12) were used. Prevalence of DM and UM were determined with 95% confidence intervals. To determine the factors associated with DM and UM, a multinomial logistic regression model was used. The prevalence of DM was 8.6% (95%CI: 8.2-9), and UM, 0.9% (95%CI: 0.8-1). People with DM more frequently visited healthcare professionals (47.8%), required more supplementary tests (86.8), had a higher percentage of hospitalization (11.3%), and used emergency services (45.1%). Women had nearly three times the risk of DM and UM. Worse mental health was a risk factor for UM (OR = 1.20) and DM (OR = 1.18). The greater the work stress, the greater the risk of DM (OR = 1.12). An adequate monitoring and management of migraine in people with these characteristics could contribute to improving their quality of life and reducing costs in the system.

Identifiants

pubmed: 34769668
pii: ijerph182111145
doi: 10.3390/ijerph182111145
pmc: PMC8583596
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Eur J Pain. 2014 Oct;18(9):1290-7
pubmed: 24700516
BMJ Open. 2020 Feb 13;10(2):e034926
pubmed: 32060163
Curr Neurol Neurosci Rep. 2018 May 31;18(7):42
pubmed: 29855724
Aten Primaria. 1996 Sep 15;18(4):153-6, 158-63
pubmed: 8962994
Curr Med Res Opin. 2016 Nov;32(11):1813-1820
pubmed: 27400416
J Pain Res. 2020 Oct 05;13:2423-2430
pubmed: 33116786
Health Technol Assess. 2002;6(32):1-244
pubmed: 12925269
Rev Neurol. 2020 Aug 1;71(3):110-118
pubmed: 32672349
Headache. 2014 Sep;54(8):1310-9
pubmed: 24898830
Headache. 2007 Apr;47 Suppl 1:S2-9
pubmed: 17425705
J Headache Pain. 2019 Feb 12;20(1):13
pubmed: 30755160
Lancet. 2021 Apr 17;397(10283):1485-1495
pubmed: 33773613
Headache. 2014 Apr;54(4):610-8
pubmed: 24666014
J Headache Pain. 2018 Nov 27;19(1):115
pubmed: 30482181
Pain. 2008 Mar;135(1-2):142-50
pubmed: 17611036
Front Neurol. 2021 Jan 18;11:613372
pubmed: 33536997
PLoS One. 2014 Oct 24;9(10):e110530
pubmed: 25343495
J Affect Disord. 2015 Nov 15;187:197-202
pubmed: 26342172
J Headache Pain. 2010 Apr;11(2):97-104
pubmed: 20012124
J Headache Pain. 2019 May 31;20(1):65
pubmed: 31151382
Headache. 2018 Feb;58(2):346-353
pubmed: 28796284
Prev Chronic Dis. 2014 Feb 27;11:E30
pubmed: 24576397
Headache. 2017 Apr;57(4):570-585
pubmed: 28185239
Cephalalgia. 2011 Apr;31(5):585-96
pubmed: 21123626
Headache. 2018 Oct;58(9):1408-1426
pubmed: 30341895
J Neurol Sci. 2017 Jan 15;372:307-315
pubmed: 28017235
Headache. 2001 Jul-Aug;41(7):646-57
pubmed: 11554952
J Headache Pain. 2019 May 9;20(1):51
pubmed: 31072313
Pain Med. 2019 Mar 1;20(3):555-563
pubmed: 29796603
Clin J Pain. 2015 Mar;31(3):273-9
pubmed: 24762867
J Gen Intern Med. 2004 Oct;19(10):1005-12
pubmed: 15482552
Pain. 2004 Sep;111(1-2):51-8
pubmed: 15327808
Cephalalgia. 2006 Jan;26(1):1-6
pubmed: 16396660
Brain Behav. 2018 Jun;8(6):e00950
pubmed: 30106228
Pharmacoeconomics. 2004;22(9):591-603
pubmed: 15209528
Lancet. 2021 Apr 17;397(10283):1496-1504
pubmed: 33773610
J Pain Res. 2015 Feb 25;8:119-30
pubmed: 25750546
J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):741-9
pubmed: 26733600
J Cell Mol Med. 2019 Jul;23(7):4505-4513
pubmed: 31106971
Eur J Neurol. 2003 Mar;10(2):147-52
pubmed: 12603289
Med Hypotheses. 2008;71(1):14-21
pubmed: 18289799

Auteurs

Alejandro Salazar (A)

The Observatory of Pain, University of Cádiz, 11009 Cádiz, Spain.
Research Unit, Biomedical Research and Innovation Institute of Cádiz (INiBICA), Puerta del Mar University Hospital, University of Cadiz, 11009 Cádiz, Spain.
Department of Statistics and Operational Research, University of Cádiz, 11510 Puerto Real, Spain.

Laura Berrocal (L)

Preventive Medicine and Public Health Area, University of Cádiz, 11009 Cádiz, Spain.

Inmaculada Failde (I)

The Observatory of Pain, University of Cádiz, 11009 Cádiz, Spain.
Research Unit, Biomedical Research and Innovation Institute of Cádiz (INiBICA), Puerta del Mar University Hospital, University of Cadiz, 11009 Cádiz, Spain.
Preventive Medicine and Public Health Area, University of Cádiz, 11009 Cádiz, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH